Lantheus is a radiopharmaceutical-focused company built around commercial radiodiagnostics such as PYLARIFY, DEFINITY and Neuraceq, while expanding newer products and pipeline assets in oncology and neurology. The company is now primarily in transaction-execution mode: Curium agreed to acquire it for $102.50 per share in cash plus CVRs worth up to $12 per share, with the shareholder vote set for October 14, 2026.
The filing adds process friction, not a changed deal. Since the definitive proxy was filed, three stockholder complaints and 16 demand letters have challenged alleged omissions around projections, Morgan Stanley’s fairness work and insider conflicts. The company responds with supplemental disclosures so the vote can proceed, while denying wrongdoing and saying the claims lack merit. 〔0〕
The new valuation detail broadly supports the previously announced consideration, but exposes a more complicated fairness picture. Morgan Stanley’s revised discounted-cash-flow range is $88.10-$118.60 per share, while its fiscal-2026 comparable-company analysis implies $63.85-$84.20; the previously announced $102.50 cash consideration sits inside the DCF range but above the public-comparables range. The analyst-target range is $98-$129, also placing the cash consideration within that reference set.
| Supplemental disclosure | Figure | Filing location |
|---|---|---|
| Morgan Stanley DCF implied value per share | $88.10-$118.60 | Opinion of Financial Advisor — Discounted Cash Flow Analysis |
| Comparable-company AV / Adjusted EBITDA range | 7.9x-10.5x | Opinion of Financial Advisor — Publicly Traded Companies Analysis |
| Comparable-company implied value per share | $63.85-$84.20 | Opinion of Financial Advisor — Publicly Traded Companies Analysis |
| Undiscounted analyst price targets | $98-$129 | Opinion of Financial Advisor — Analysts’ Price Targets |
| Morgan Stanley fees from Lantheus | $5M-$10M | Opinion of Financial Advisor — General |
| Morgan Stanley stock interest | 2%-3% | Opinion of Financial Advisor — General |
The most market-relevant new information is banker and insider scrutiny. Morgan Stanley disclosed $5 million-$10 million of prior fees from Lantheus, another $5 million-$10 million from certain CapVest affiliates, possible future work for the transaction parties, and a 2%-3% aggregate interest in Lantheus stock. The proxy also now says executives could discuss post-closing employment or equity arrangements with Parent, even though none had been agreed as of the proxy date. 〔1〕
The disclosure strategy is defensive but practical. The company says it is supplementing the proxy solely to avoid litigation cost and uncertainty and allow shareholders to vote, rather than because it concedes the original proxy was deficient. That makes this less a change to Lantheus’s operating business than a sign that closing now carries additional legal and procedural noise.
Bottom line: The merger economics are unchanged, but the path to approval is noisier than previously disclosed. The supplemental valuation and conflict information helps clear the way for the vote, while the lawsuits and demand letters modestly weaken the deal-process read without yet showing that the transaction itself is failing.
Read the original 8-K on SEC EDGAR ↗